Among numerous clinical candidates, agonists of the Farnesoid X receptor (FXR), such as the bile acid derivative, obeticholic acid and non‐steroidal agents, such as Tropifexor, are in advanced clinical trials for NASH.28 The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.